12/17
07:20 am
dyai
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets
Low
Report
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets
12/15
07:20 am
dyai
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins
Medium
Report
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins
12/2
03:41 pm
dyai
Dyadic International (NASDAQ:DYAI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Dyadic International (NASDAQ:DYAI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
07:25 am
dyai
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
Medium
Report
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
11/12
09:08 pm
dyai
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:05 pm
dyai
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
Medium
Report
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
11/11
08:22 am
dyai
Dyadic International Inc (DYAI) Q3 2025 Earnings Report Preview: What To Expect [Yahoo! Finance]
Low
Report
Dyadic International Inc (DYAI) Q3 2025 Earnings Report Preview: What To Expect [Yahoo! Finance]
11/10
07:25 am
dyai
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
High
Report
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
11/8
02:45 am
dyai
How Analyst Views on Dyadic International Are Shifting With New Commercialization and Partnership Risks [Yahoo! Finance]
High
Report
How Analyst Views on Dyadic International Are Shifting With New Commercialization and Partnership Risks [Yahoo! Finance]
10/29
07:25 am
dyai
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
Low
Report
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
10/23
08:02 am
dyai
Dyadic International (NASDAQ:DYAI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.
Medium
Report
Dyadic International (NASDAQ:DYAI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.
10/8
12:19 pm
dyai
Dyadic International (NASDAQ:DYAI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Dyadic International (NASDAQ:DYAI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/6
08:30 am
dyai
Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
High
Report
Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments